The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
EFFECTOR THERAPEUTICS INC | COM | 28202V108 | 2,387,740 | 6,822,114 | SH | SOLE | 6,822,114 | 0 | 0 | |||
DESIGN THERAPEUTICS INC | COM | 25056L103 | 37,657,767 | 6,526,476 | SH | SOLE | 6,526,476 | 0 | 0 | |||
ARCELLX INC. | COMMON STOCK | 03940C100 | 169,455,216 | 5,500,007 | SH | SOLE | 5,500,007 | 0 | 0 | |||
NKARTA INC. | COM | 65487U108 | 4,733,332 | 1,333,333 | SH | SOLE | 1,333,333 | 0 | 0 | |||
ARS PHARMACEUTICALS | COM | 82835W108 | 26,123,999 | 4,012,903 | SH | SOLE | 4,012,903 | 0 | 0 |